84 |
Antithrombotic Strategy in HBR Patients: Updated Strategy |
Joo-Yong Hahn |
Nov. 27. 19 |
83 |
Antithrombotic and Antiplatelet Choice in Complex PCI |
Duk-Woo Park |
Nov. 27. 19 |
82 |
The Role of Triple Antiplatelet Therapy in Patients with High Risk |
Young-Hoon Jeong |
Jul. 22. 09 |
81 |
Tailoring Treatment to Risk in Antiplatelet Therapy |
Alexandra J. Lansky |
Jul. 22. 09 |
80 |
What Is the Optimal Duration of DAPT Following DES Treatment? |
David E. Kandzari |
Jul. 22. 09 |
79 |
Anti-Platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib |
Roxana Mehran |
Jul. 22. 09 |
78 |
Strategic Approaches to Obtain Better and Earlier CV Outcome |
Weon Kim |
Jul. 22. 09 |
77 |
Does the Efficacy of Bivalirudin During PCI Depend on Clopidogrel Pretreatment? |
Matthew Price |
Jul. 22. 09 |
76 |
STEMI and NSTEMI Pharmacology Confusion: How to Choose and Use Antithrombins (Unfractionated and Low Molecular Weight Heparins, Bivalirudin, Fondaparinux) and Antiplatelet Agents (Aspirin, Clopidogrel, and Prasugrel) |
Gregg W. Stone |
Jul. 22. 09 |
75 |
Systemic Therapy for Plaque Stabilization: New Drugs Targeting LP-PLA2 |
Patrick W. Serruys |
Jul. 22. 09 |